Please assess the completion status of the following clinical trial:

Trial Title: Body Temperature in Persons With Tetraplegia When Exposed to Cold

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* (1) Between 18 and 68 years of age;~* (2) Duration of injury ≥ 1 year; (2) Level of SCI C3-T1;~* (3) Euhydration (subjects will be instructed to avoid caffeine and alcohol, maintain normal salt and water intake, and avoid strenuous exercise for 24 hours prior to study)~Exclusion Criteria:~* (1) Known coronary heart, kidney, peripheral vascular or cerebral vascular disease;~* (2) High blood pressure;~* (3) Untreated thyroid disease;~* (4) Diabetes mellitus;~* (5) Acute illness or infection;~* (6) Dehydration;~* (7) Known allergies to midodrine hydrochloride;~* (8) Smoking;~* (9) Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 68 Years
- Healthy Volunteers: t

Study Arms:
- No Drug: Tetraplegia (Type: NO_INTERVENTION): Tetraplegia: Lesion level T1 and above, American Spinal Injury Association (ASIA) impairment levels A and B, ages 18-68 years.~Exposure of up to 2 hours in a cool room.
- No Drug: AB Controls (Type: NO_INTERVENTION): AB Controls: Matched for age and gender to subjects with tetraplegia. Exposure of up to 2 hours in a cool room.
- Drug (midodrine): Tetraplegia (Type: EXPERIMENTAL): Persons with tetraplegia who completed Visit 1 (no drug). Participants are administered midodrine hydrochloride (10 mg tablet) by a physician before exposure of up to 2 hours in a cool room. (Visit 2)

Based on this trial design, predict the completion outcome and termination type (if applicable).